PubMed | Monmouth Medical Center and Chongqing Tumor Hospital
Type: Journal Article | Journal: Medical physics | Year: 2017
Safe treatment of the maximum tolerable brain metastases with GK in single patient-clinical findings METHODS: A patient diagnosed with stage IV NSCLC has received 6 courses of Gamma Knife radiosurgery (GKRS) treatments. The plans were generated with GammaPlan (version 10.1.1), six courses of treatment were administered in 2.5 years. A total of 53 metastases were treated with retreatment foci (n = 5) and planned on newly identified lesions (n = 48). Individual prescription dose varied from 12 Gy to 24 Gy.The homogeneity index (HI) was evaluated as the ratio of maximum dose to prescription dose (HI = (D2%-D98%) /DRx). The gradient index (GI) was evaluated as the ratio of prescription isodose volume (PIV) at half of the prescription isodose line to PIV (GI = PIV1/2 / PIV). Composite dose of brain from all six courses was generated on Velocity AI (version 3.0.1). All V5, V10, and V12 of brain were estimated.Mean target volume was 0.39 0.96 cmWith exceptional steep dose gradients, GKRS is ideal to treat multiple metastases in continuous courses. The hot spots were observed in the overlapped area for the given high prescription dose with no side effects.GKRS has advantages of treating multiple brain metastases from NSCLC with low whole brain dose. Our data presented conclusions of excellent local control of large numbers of metastases being treated on GKRS with superior clinical outcome.
Pu L.,Chongqing Medical University |
Jing S.,Chongqing Medical University |
Bianqin G.,Chongqing Medical University |
Ping L.,Chongqing Medical University |
And 9 more authors.
Hepatitis Monthly | Year: 2013
Background: Y-box binding protein 1 (YB-1) overexpression has been shown in various tumor cells including hepatocellular carcinoma (HCC); moreover, this protein can be actively secreted. Objectives: The aim of this study was to establish a method to quantify serum YB-1 and evaluate its clinical application in the clinical diagnosis of HCC.Patients and Methods: Recombinant YB-1 and two populations of its antibodies were prepared. A monoclonal antibody was specific to the N-terminus of YB-1 amino acids 134-160; and another was a polyclonal antibody. A sandwich-type chemiluminescence immunoassay (CLIA) was developed and evaluated. Levels of YB-1 and alpha fetoprotein (AFP) in serum samples from 105 HCC patients, 25 hepatitis B viruspatients, 25 cirrhosis patients, and 50 healthy donors were detected using the established method and an AFP electrochemiluminescence kit. Results: The developed method was linear to 150 μg/L of YB-1 with a minimum detection limit of 0.01 μg/L. The average recoveries were between 93.9% and 109.0%. The mean intra- and inter-assay coefficients of variation (CVs) were 4.0-4.8% and 8.2-10.2%, respectively. The relationship between the concentration of diluted YB-1 and the dilution ratios gave a good linear correlation coefficient of 0.9986. The YB-1 concentration was increased in serum of HCC patients (33.0 ± 23.39 μg/L) compared to healthy individuals (13.2 ± 5.29 μg/L, P < 0.0001), patients with HBV (17.9 ± 7.49 μg/L, P = 0.0003), and patients with HBV cirrhosis (20.7 ± 8.75 μg/L, P < 0.05). Moreover, the combination of YB-1 and alpha-fetoprotein had a high sensitivity (89.5%) and reasonable specificity (62.0%) in identifying HCC. Conclusions: The established method has an acceptable performance in quantifying YB-1. In addition, serum YB-1 may aid in the diagnosis of HCC. DOI: 10.5812/hepatmon © 2013, Kowsar Corp.
Nian W.,Chongqing Tumor Hospital |
Nian W.,Chongqing Medical University |
Ao X.,Chongqing Medical University |
Ao X.,Peoples Hospital of Huangshan |
And 7 more authors.
Oncology Letters | Year: 2013
microRNAs (miRNAs) have been hypothesized to function as oncogenes or tumor suppressors by targeting specific cancer-related genes. Previous studies have reported that miR-223 may serve as a tumor suppressor in a number of cancer types, however, knowledge of its targets in non-small cell lung cancer (NSCLC) remains limited. In the current study, miR-223 was found to inhibit cell proliferation in vitro by CCK-8 assay, growth curves and an anchorage-independent growth assay in a Lewis lung carcinoma (LLC) cell line. miR-223 transfection in the LLC cells was observed to significantly inhibit migration and invasion, induce G2/M arrest and decrease the expression levels of Sca-1, a marker of murine stem cells. In addition, miR-223 transfection markedly suppressed AKT and ERK signaling, as well as insulin-like growth factor-1 receptor (IGF-1R)-mediated downstream signaling, pathways that are crucial for cell proliferation and invasion in NSCLC cells. Analyses in C57BL/6 mice demonstrated that miR-223 suppresses tumorigenicity in vivo. Using a luciferase activity assay and western blot analysis, IGF-1R and cyclin-dependent kinase 2 (CDK2) were identified as direct targets of miR-223. In the present study, novel cancer-related targets of miR-223 were identified and verified in a LLC cell line, indicating that miR-223 functions as a tumor suppressor, which may fine-tune the activity of the IGF-1R pathway in lung cancer. Therefore, increasing miR-223 expression may provide a novel approach for the treatment of NSCLC.